2025 NEXT Summit

Session 2: Interventional Oncology: Transarterial Therapies Primer

Moderators: Kirema Garcia-Reyes, MD (IO) and Adam Burgoyne, MD, PhD (Medical Oncology)

Chemoembolization: Current State of the Science | Kelvin Hong, MBBCH

Radioembolization: Radiation Basics of Y90 | S. Cheenu Kappadath, PhD, FAAPM

Resin Microsphere Dosimetry
Marnix Lam, MD, PhD
Glass Microsphere Dosimetry
Christopher D. Malone, MD


Session 3: Biomarkers
Moderators: Terence P. Gade, MD, PhD, (IO) and Amit Singal, MD (Medical Oncology)

Keynote: How Does Immunotherapy Fit with Locoregional Therapies
Amit Singal, MD

Immunological Effects of Local Therapies in the Tumor Microenvironment
Rony Avritscher, MD
Unraveling Mechanisms of Resistance to Immunotherapy in HCC

Luciane Tsukamoto Kagohara, PhD

Imaging Biomarkers of Response to Immuotherapy in Liver Cancer
Aliya Qayyum, MD

Minimal Residual Disease after TACE
 Renumathy Dhanasekaran, MD

Session 4: Sequencing
Moderators: Thomas Helmberger, MD, (IO) and Amit Singal, MD (Medical Oncology)

Clinical Rationale for Different Sequencing Strategies
Tim F. Greten, MD

Impact of Various Interventional Modalities on Sequencing Rationale
 Terence P. Gade, MD, PhD

Tumor Heterogeneity and Combination Therapies
Luciane Tsukamoto Kagohara, PhD

Managing Adverse Event of Combination Therapies
Adam Burgoyne, MD, PhD

Friday, 6 June

Session 5: Combination Therapies (IO + IO)
Moderators: Edward Kim, MD, FSIR, (IO) and Stephen L. Chan, MBBS, MD, FRCP, FHKCP, FHKAM (Hepatology)

EMERALD-1 and LEAP-012
Lingling Du, MD

Will Combination Therapy Impact My Practice: Oncology Perspective
Stephen L. Chan, MBBS, MD, FRCP, FHKCP, FHKAM

Will Combination Therapy Impact My Practice: Hepatology Perspective
Anjana Pillai, MD

Will Combination Therapy Impact My Practice: Surgical Perspective
Myron E. Schwartz, MD

TARE: Ongoing Trials and IR Perspective of EMERALD-1 and LEAP-12
Christopher D. Malone, MD

Session 6: TARE or...
Moderators: Robert J. Lewandowski, MD, FSIR, Nora Tobori, MD

Solitary HCC: Ablative SBRT
Stanley Liauw, MD

Solitary HCC: Radiation Segmentectomy
Beau Toskich, MD

BTC: HAI Pump
Alice Wei, MD, MSc

BTC: TARE
William Rilling, MD, FSIR

Multifocal Bilobar HCC: Systemic Therapy Alone
William P. Harris, MD

Multifocal Bilobar HCC: TACE
Kelvin Hong, MBBCH

Multifocal Bilobar HCC: TARE
Nima Kokabi, MD

Session 7: Practical y90
Moderators: Siddharth A. Padia, MD, and Robert J. Lewandowski, MD, FSIR

Radiation Lobectomy
Robert J. Lewandowski, MD, FSIR

Flow Diversion: What is it and Why?
Beau Toskich, MD

Extra-Hepatic Supply
Kirema Garcia-Reyes, MD

High Lung Shunts
John D. Louie, MD

Lessons Learned from the European Perspective of TARE
Thomas Helmberger, MD

Lessons Learned from the Korean Perspective of TARE
 Jin Woo Choi, MD, PhD

Vascular Invasion in the Era of Immunotherapy
Siddharth A. Padia, MD

Session 8: Multidisciplinary Case Review 1: Curative Intent
Moderator: Riad Salem, MD, MBA

HCC: Solitary HCC Beyond T2 with Elevated AFP
Myron E. Schwartz, MD

HCC: Multi-focal within Downstaging Criteria
Kelvin Hong, MBBCH

CRC Transplant Downstaging
Daniel B. Brown, MD, FSIR

HCC: Unilobar VP3 Invasion
Stephen L. Chan, MBBS, MD, FRCP, FHKCP, FHKAM
Stanley Liauw, MD

Session 9: Multidisciplinary Case Review 2: Palliative Intent
Moderator: Siddarth A. Padia, MD

HCC: Infiltrative HCC with Elevated AFP
Nora Tabori, MD

HCC: Large Solitary Tumor
Anjana Pillai, MD

HCC: Unilobar with Pulmonary Mets
Jin Woo Choi, MD, PhD

BTC: Recurrence Post-resection
Beau Toskich, MD
William P. Harris, MD;
Alice Wei, MD
Stanley Liauw, MD